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Abstract 
 
A series of novel (C^N^N) cyclometalated AuIII complexes of general formula [Au(bipydmb-
H)X][PF6] (bipydmb-H = C^N^N cyclometalated 6-(1,1-dimethylbenzyl)-2,2’-bipyridine) were 
prepared with a range of anionic ligands X in fourth coordination position, featuring either C- 
(alkynyl), N-, O- or S-donor atoms. The X ligands are varied in nature, and include three 
coumarins, 4-ethynylaniline, saccharine, thio-β-D-glucose tetraacetate, the tripeptide 
glutathione (GSH) and a coumarin–substituted amide derived from 4-ethynylanilyne. The 
gold(I) complex [Au(C2ArNHCOQ)(PPh3)] (HC2ArNHCOQ = N-(4-ethynylphenyl)-2-oxo-2H-
chromene-3-carboxamide) was also prepared for comparison. The new compounds were fully 
characterized by means of analytical techniques, including NMR, absorption and emission 
spectroscopy. The crystal structures of three cyclometalated AuIII complexes and of the AuI 
derivative were solved by single crystal X-ray diffraction. The antiproliferative activity of the 
new AuIII cyclometalated derivatives was evaluated against cancer cells in vitro. According to 
the obtained results, only complexes 3-PF6 and 5-PF6, featuring coumarins as ancillary 
ligands, and endowed with high redox stability in solution, display antiproliferative effects, with 
5-PF6 being the most potent, while all the others are scarcely active to non-active in the 
selected cell lines. In order to study the reactivity of the compounds with biomolecules, the 
interaction of complexes 3-PF6 and 5-PF6 with the protein cytochrome c and the amino acids 
cysteine and histidine was analysed by electrospray ionization mass spectrometry (ESI MS), 
showing adduct formation only with Cys after at least 1 h incubation. Furthermore, the parent 
hydroxo complex [Au(bipydmb-H)(OH)][PF6], 1OH-PF6, was investigated in a competitive assay 
to determine the protein vs. oligonucleotide binding preferences by capillary zone 
electrophoresis (CZE) coupled to ESI MS. Of note, the compound was found to selectively 
form adducts with the oligonucleotide over the protein upon ligand exchange with the 
hydroxido ligand. Adduct formation occurred within the first 10 min incubation, demonstrating 
the preference of 1OH-PF6 for nucleotides in this setup. Overall, the obtained results point 
towards the possibility to selectively target DNA with gold(III) organometallics. 
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INTRODUCTION 
 
While the application of gold in medicine dates back to several thousand years, research into 
gold-based drugs has recently seen a renaissance.1 Within this research area, organometallic 
gold complexes have been particularly explored as anticancer therapeutics, mainly due to their 
higher stability in physiological conditions guaranteed by the presence of a direct Au-C bond.1-
2 In this context, AuIII complexes stabilized by C^N cyclometalated ligands represent a versatile 
class of organometallics which have found several applications due to their unique 
physicochemical properties3 that have been the subject of a number of investigations.4-6 Also 
intensely investigated are the applications of these complexes in the field of bioinorganic 
medicinal chemistry.2,7-9 Indeed, the superior stabilization of the gold(III) ion against reduction 
in aqueous solution, granted by C^N cyclometalated ligands with respect to, for example, N^N 
chelating ones, gave new impetus to the search of possible alternatives to platinum(II)-based 
anticancer agents. The first examples of cyclometalated AuIII complexes as potential 
anticancer agents were those based on the C^N ligand 2-(N,N-dimethylamino)methylphenyl.10-
11 Those complexes displayed higher cytotoxic activity than cisplatin against human cancer 
cells in vitro and antitumor activity comparable to the Pt(II) anticancer drug cisplatin in vivo.10-11 
Following these successful results, a number of other cyclometalated AuIII complexes 
supported by C^N chelates as well as by C^N^N, N^C^N and C^N^C pincer ligands, endowed 
with promising anticancer properties and unique mechanisms of action, have been reported.2,7-
9,12 These complexes also present the advantage of tolerating a large palette of ancillary 
ligands such as phosphanes,13-14 NHCs,15 and N-donor ligands,16 enabling optimization of their 
biological properties. In general, for such different families of gold(III) cyclometalated 
compounds, interactions with protein targets are considered to be responsible for their 
observed anticancer effects,9,17-18 whereas interactions with DNA seem less relevant, with a 
few exceptions.19-20  
Within this research area, several years ago some of us reported the synthesis and 
biological activity of the hydroxo complex [Au(bipydmb-H)(OH)][PF6]21 (1OH-PF6, bipydmb-H = 
C^N^N cyclometalated 6-(1,1-dimethylbenzyl)-2,2’-bipyridine)) and successively of other 
complexes derived from this precursor, namely the amido complexes [Au(bipydmb-
H)(NHAr)][PF6] (Ar = C6H4Me-4; C6H3Me2-2,6),22 and the acetimidate complex [Au(bipydmb-
H){NH(CO)Me}][PF6].23 The three compounds manifest rather similar chemical properties 
being stable in solution and moderately active in cancer cells.22-23 Reactions with proteins lead 
to formation of different amounts of metalated adducts, as evidenced by mass spectrometry, 
where a single {Au(bipydmb-H)} fragment is invariably linked to the protein.23 Nevertheless, the 
reactivity of the compounds is different depending on the type of ancillary ligand used, with the 
acetimidate complex [Au(bipydmb-H){NH(CO)Me}][PF6] being the least reactive.23 
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In order to further explore the biological properties of this family of C^N^N complexes, 
we report here on the synthesis, structural characterization and biological activity of new 
cyclometalated AuIII derivatives of general formula [Au(bipydmb-H)X]+ and a range of anionic 
ligands X in the fourth position, featuring either C-, N-, O- or S-donor atoms. The X ligands 
include three coumarins, 4-ethynylaniline, saccharinate, thio-β-D-glucose tetraacetate, the 
tripeptide glutathione (GSH) and a coumarin substituted amide, derived from 4-ethynylanilyne, 
synthesized in this study. The gold(I) complex [AuX(PPh3)], where X is the new ligand N-(4-
ethynylphenyl)-2-oxo-2H-chromene-3-carboxamide, was also prepared for comparison.  
The choice of coumarins was motivated by their pharmacological activities, including 
anticancer activity,24 and for their photophysical properties. Coumarin fluorochromes are small 
and biocompatible, and are widely used for in vivo and in vitro diagnostics and imaging.25-26 As 
for saccharine, it was supposed to confer higher water solubility to the resulting complex and 
aspects of the biological profile of a number of saccharinate AuI and AuIII complexes were 
investigated by some of us.27 Thio-β-D-glucose tetraacetate is the ancillary ligand of the 
antiarthritic drug auranofin, the latter recently being investigated for potential therapeutic 
application in a number of other diseases including cancer, neurodegenerative disorders, 
HIV/AIDS, parasitic infections and bacterial infections.28 Thus, this moiety has been widely 
used as ancillary ligand in a variety of metal-based drugs, due to its capability to facilitate 
uptake into cancer cells by modulating the lipophilic/hydrophilic character, as well as via 
possible interaction with GLUT1 transporters.29-30 Finally, the tripeptide glutathione is 
ubiquitous in cells where it exerts many roles: it acts as an antioxidant, a free radical 
scavenger and a detoxifying agent. Heavy metal ions are mainly removed by GSH after 
coordination to the thiol group. However, studies also postulated the role of GSH adduct 
formation in the mechanisms of toxicity of cisplatin;31 thus, the design of metal-GSH 
complexes could be exploited as a strategy to increase the anticancer effects of experimental 
metallodrugs. This notwithstanding, well defined GSH metal complexes are still rare.32-34 
Thus, the new compounds were studied for spectroscopic properties, as well as for 
their antiproliferative effects in a small panel of human cancer cell lines and against non-
tumorigenic cells from embryonic kidney (HEK-293) in vitro. In order to characterize the 
compounds with biological nucleophiles, some of the most cytotoxic derivatives were studied 
for their reactivity with the model protein cytochrome c (cyt c) and mixtures of amino acids by 
Electrospray Ionization Mass Spectrometry (ESI MS). Furthermore, capillary zone 
electrophoresis (CZE)–ESI MS allowed to determine the preference for the compounds’ 
binding to a single strand oligonucleotide (5´-dATTGGCAC-3´) in competition experiments with 
the model protein ubiquitin (ub).35 For the first time, we observed some of the AuIII C^N^N 
compounds to display remarkable affinity for nucleic acid binding, which may pave the way to 
the exploitation of these organometallic scaffolds to selectively target DNA structures. 
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RESULTS AND DISCUSSION 
 
Synthesis and Characterization 
The eight new cyclometalated AuIII compounds 2-PF6 to 9-PF6, of general formula [Au(bipydmb-
H)X][PF6] (where bipydmb-H = cyclometalated 6-(1,1-dimethylbenzyl)-2,2’-bipyridine, Figure 1) 
are characterized by a common terdentate C^N^N structural motif, while the anionic X ligands 
in the fourth position are varied in nature. These include: the deprotonated form of three 
commercially available coumarins, namely 2-oxo-2H-chromene-3-carboxylic acid (QCO2H), 7-
mercapto-4-methyl-2H-chromen-2-one (MeQSH) and 7-amino-4-(trifluoromethyl)-2H-chromen-
2-one (CF3QNH2), and the coumarin substituted amide N-(4-ethynylphenyl)-2-oxo-2H-
chromene-3-carboxamide (HC2ArNHCOQ) synthesized in this study, 4-ethynylaniline 
(HC2ArNH2), saccharine (SaccH), thio-β-D-glucose tetraacetate (GluSH) and the tripeptide 
glutathione (GSH).  
 
 
 
Figure 1. Structures of the AuIII complexes [Au(bipydmb-H)X][PF6] 2-PF6 – 9-PF6. 
 
 
The new ligand HC2ArNHCOQ was obtained by condensation reaction of 4-ethynylaniline 
(HC2ArNH2) and coumarin-3-carboxylic acid (QCO2H) in the presence of N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) as the coupling reagent (Scheme 1). 
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Scheme 1. Synthesis of the ligand HC2ArNHCOQ (N-(4-ethynylphenyl)-2-oxo-2H-chromene-3-
carboxamide). 
 
The new gold(III) complexes were obtained by σ-ligand metathesis reaction of the 
cyclometalated precursors [Au(bipydmb-H)Y][PF6] {Y = OH (1OH-PF6), OMe (1OMe-PF6) or 
CH2C(O)Me (1CH2Ac-PF6)} with the neutral HX ligand or from the chlorido complex {Y = Cl 
(1Cl-PF6)} and the MX salt (M = Na or K), depending on the acidity of the HX ligand (see 
Experimental section and Schemes 2 and 3). The precursors 1Y-PF6 were synthesized as 
previously described by Cinellu et al.36-38 
 
 
 
 
Scheme 2. Synthesis of complexes 2-PF6, 3-PF6, 8-PF6, and 9-PF6 from the precursor 1OH-PF6. 
 
 
The reaction of the more acidic ligands QCO2H, MeQSH, GluSH, and GSH with the hydroxo 
complex 1OH-PF6 proceeds smoothly, in dichloromethane or aqueous solution (GSH), at room 
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temperature, to give, respectively, the carboxylato complex 2-PF6 and the thiolato complexes 
3-PF6, 8-PF6 and 9-PF6 in good yields. Under the same reaction conditions, and also in 
toluene at 80 °C, only small amounts of complex 5-PF6 were obtained from reaction with the 
less acidic ligand HC2ArNHQ as the competitive condensation reaction of 1OH-PF6 to give the 
dinuclear oxo-bridged complex [Au2(µ-O)(bipydmb-H)2][PF6]239 occurred more rapidly. To 
overcome this undesired side-reaction, the methoxo 1OMe-PF6 or the acetonyl 1CH2Ac-PF6 
complexes were used as the cyclometalated precursors. The amido complex 4-PF6 was 
obtained from the reaction of CF3QNH2 with 1OMe-PF6 in CH2Cl2 at room temperature 
(Scheme 3). Unexpectedly, no reaction occurred between any of the 1Y-PF6 (Y = OH, OMe or 
CH2Ac) and HC2ArNH2, nevertheless the alkynyl complex 6-PF6 could be obtained from 
reaction with the chlorido complex 1Cl-PF6 in the presence of tBuOK in ethanol solution 
(Scheme 3). The saccharinate complex 7-PF6 was obtained from reaction of SaccNa with 1Cl-
PF6 in water. 
 
 
 
Scheme 3. Synthesis of complexes 5-PF6 and 4-PF6 from the precursor 1OMe-PF6 and of 6-PF6 and 7-
PF6 from the precursor 1Cl-PF6. 
 
 
The gold(I) complex 10 was synthesized by reaction of [AuCl(PPh3)] with the new ligand 
HC2ArNHCOQ in methanol in the presence of tBuOK (Scheme 4). 
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Scheme 4. Synthesis of the AuI complex 10. 
 
 
The new gold(III) cyclometalated complexes 2-PF6 – 9-PF6 and the gold(I) complex 10 are 
fairly stable both in the solid state and in solution and were fully characterized by means of 
analytical and spectroscopic techniques. With the exception of the water-soluble glutathione 
derivative 9-PF6, all the complexes are soluble only in organic solvents. The FT-IR spectra 
recorded in the range 4000–600 cm-1 show the peaks that are attributed to the cyclometalated 
bipydmb ligand and to the ancillary ligands. The NMR (1H), IR and UV-vis spectroscopic data of 
the gold(III) complexes 2-PF6 – 9-PF6 and for the gold(I) complex 10 are listed in the 
Experimental section and are consistent with the expected structures, which for complexes 2-
PF6, 3-PF6, 6-PF6 and 10 were confirmed by single-crystal X-ray analysis (see below). 
The 1H NMR spectrum of each complex (Figures S1–S12) shows the resonances of 
the cyclometalated bipydmb and the ancillary ligand in the expected 1 : 1 integral ratio. In all 
cases, the signal of the H6’ proton (numbering scheme as in the Experimental), i.e. that in 
proximity of the ancillary ligand, is the most deshielded one (with the exception of the NH of 
complex 5-PF6), and the most sensitive to the donor atom of the ancillary ligand, as usually 
observed for this kind of complexes.36-38 Within this series, the highest downfield shifts (with 
respect to the free ligand) are observed for complexes 5-PF6 and 6-PF6, both featuring a C-
donor ligand, followed by 3-PF6, 8-PF6 and 9-PF6, featuring an S-donor ligand. Moreover, the 
H3” proton, in ortho position to the metalated carbon atom of the bipydmb ligand, undergoes a 
downfield shift, although to a lesser extent with respect to the H6’. 
In all cases, with the exception of complexes 8-PF6 and 9-PF6, only one set of signals 
is observed. Notably, complexes 5-PF6 and 6-PF6, whose ancillary ligands (HC2ArNHCOQ and 
HC2ArNH2) possess two activable protons, i.e. N-H (amidic in the former and aminic in the 
latter) and methynic C-H, only the latter is activated leading to the alkynyl derivatives as shown 
by the absence of the signal of the methynic proton at 3.05 and 3.16 ppm in the free ligands. 
Two sets of signals are instead observed for complexes 8-PF6 and 9-PF6, with integral ratios 
of 1:0.2 and 1:0.1, respectively. In the case of the thio-glucose tetraacetate derivative 8-PF6, 
the two species are likely diastereomers due to the chiral nature of the ligand, and an 
analogous coordination behaviour was previously observed in the cyclometalated derivative 
[Au(pyb-H)(GluS)2] (pyb-H = cyclometalated 2-benzylpyridine).13 In the case of complex 9-PF6, 
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due to the number of activatable protons, the two species are likely bond isomers: the major 
one being undoubtedly the S-bonded isomer while the minor species is likely an O-bonded 
derivative, as suggested by the very different chemical shifts of the H6’ proton of the two 
isomers: 9.30 ppm (major species) and 8.74 ppm (minor species); these values are in line with 
those observed respectively for the S-donor and O-donor ligand derivatives (see above). 
Strong evidence of coordination to the deprotonated thiol group is provided by the resonance 
of methylene protons CH2-5x that in the free ligand gives rise to one multiplet (due to coupling 
to SH and H4x) at 2.95 ppm, while in the complex it appears as an AB quartet - with each 
signal further split by coupling with H4x – centred at 3.13 ppm (JAB = 13.4 Hz). Moreover, 
disappearance of the S-H stretching vibration at 2525 cm-1 further supports deprotonation and 
coordination of the thiol group. As shown by the 1H and 31P{1H} NMR spectra (Figure S13), 
only the alkynyl derivative was formed also in the case of the gold(I) complex 10. 
Acetonitrile solutions of all the new AuI/III complexes 1Cl-PF6, 1OH-PF6, 1OMe-PF6, 2-
PF6 – 9-PF6 and 10 feature peculiar UV–Vis absorption bands in the region between 220 and 
350 nm (Table S1). An analysis of the absorption spectra recorded on solutions at 
concentrations systematically varied between 2.6·10–5 and 1·10–4 M does not show any 
evidence of intermolecular interactions. Most of the spectra of the gold(III) complexes display 
two or three groups of bands, falling at different energies: 
(i) All the UV-Vis absorption spectra display an intense and broad UV band, whose 
maximum falls below 220 nm. According to what was established for AuIII square-planar 
complexes deriving from the 2-(2'-pyridyl)benzimidazole (pbiH) ligand,40 this band could be 
tentatively attributed to the overlap of numerous singlet transitions, also involving low lying 
Molecular Orbitals (MOs) with significant contributions from the 5d Atomic Orbitals (AOs) of 
the gold metal ion.  
(ii) The absorption bands in the range 240–330 nm, in many cases overlapped by the 
more intense UV absorption (see above), can be envisaged in the electronic spectra of the 
ligands and can be therefore attributed to interligand (IL) transitions.  
(iii) All AuIII complexes display a band, featuring a maximum in the range 320–330 nm, at 
energies lower than those of the lowest energy bands of the relevant ligands. This band is 
significantly red-shifted to 410 nm in 4-PF6 (Figure 2). In agreement to previous theoretical 
results36 and to what was previously proposed for 1Cl-PF6 and 1OH-PF6,21 this band features a 
partial Ligand-to-Metal Charge-Transfer (LMCT) character.  
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Figure 2. Overlay of the UV-Vis (220–500 nm) absorption spectrum (normalized on the peak at 325 nm; 
molar extinction coefficient in parentheses) and the normalized emission spectrum (λexc = 325 nm) 
recorded for 4-PF6 [2.52·10-5 M] in acetonitrile solution.  
 
 
Concerning the neutral AuI complex 10, in addition to the intense UV absorption, whose tail 
can be seen in the range 220–260 nm, two sets of absorption band can be observed, namely 
a structured band, centered at 298 nm, and a very broad band (half-bandwidth 90 nm) at 
about 345 nm (Figure S14), that can be attributed to a MLCT transitions based on the DFT 
calculations carried out on the neutral complex [AuI(pbi)Cl].40 
The emission properties of the synthesized complexes were measured at r.t. in 
acetonitrile solution (Table S1). The bipydmb ligand features a well-defined emission band at 
λem = 384 nm. All the complexes of the type [Au(bipydmb-H)X][PF6] featuring a non-emissive 
ancillary ligand X (1Cl-PF6, 1OH-PF6, 1OMe-PF6, 8-PF6, 9-PF6) display a single emission peak 
at about 350 nm, therefore being tentatively attributed to the perturbed emission of the bipydmb 
ligand. The same emission energy is shown by 6-PF6 (Table S1). Notably, the emission energy 
of these complexes matches that observed in diluted CH2Cl2 solution for [Au(bpi)Cl2] and 
[Au(pbi)(AcO)2] (λem = 360 nm), showing a common AuIII(N^N) coordination environment.40 
Since complexes 3-PF6 and 5-PF6, featuring emitting ancillary ligands, show similar emission 
properties (λem = 374 and 365 nm, respectively), it should be inferred that the peculiar 
emission of the coumarine-based ancillary ligands (λem = 381 and 465 nm for MeQSH and 
HC2ArNHCOQ, respectively) would be quenched upon coordination to the metal ion. The 
typical emission of coumarin is instead preserved in the case of the complexes 2-PF6 (Figure 
S15) and 4-PF6 (Figure 2), which show low-energy emission bands in the visible region (λem = 
410 and 462 nm, respectively) at roughly the same energy as the uncoordinated ligands (λem = 
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415 and 470 nm for QCO2H and CF3QNH2, respectively). Similarly, complexes 7-PF6 and 10 
(Table S1 and Figure S16) feature emission bands in the same wavelength range (435-470 
nm) as the starting sodium saccharinate and HC2ArNHCOQ precursors (λem = 440 and 460 
nm, respectively). This suggests that the MOs of chromophores involved in the luminescence 
of the complexes 2-PF6, 4-PF6, 7-PF6, and 10 do not mix significantly with the AOs of the 
metal ion in the resulting complexes. In general, the emission intensity of the complexes is 
sensibly lower than that of the related free ligands.  
The total or partial quenching of the emission of the ligands observed under 
coordination could be tentatively attributed to InterSystem Crossing (ISC). In line with what 
was discussed based on QM calculations carried out on different AuI/III complexes,40 the spin-
forbidden ISC is induced by the interaction between the electronic spin and orbital moments. 
Since the spin-orbit coupling constant depends on the fourth power of the effective nuclear 
charge,41 ISC is increased in molecular systems containing heavy atoms, such as gold. ISC 
relies on the overlap between the vibrational wavefunctions of the initial (singlet) and the final 
(triplet) states, so that pairs of quasi-degenerate states of different spin multiplicity are good 
candidates to be involved in ISC processes, especially when ligands with a large degree of π-
electron delocalization are present in the complexes. Consequently, ISC may provide an 
alternative relaxation path with respect to fluorescence, thus accounting for the lower emission 
featured by the complexes as compared to the corresponding emitting ligands. 
 
Crystal Structures of Complexes 2-PF6, 3-PF6, 6-PF6 and 10 
For three of the AuIII complexes, namely [Au(bipydmb-H)(QCO2)][PF6], 2-PF6, [Au(bipydmb-
H)(MeQS)[PF6], 3-PF6, [Au(bipydmb-H)(C2ArNH2)], 6-PF6, and for the gold(I) complex 
[Au(C2ArNHCOQ)(PPh3)], 10, the structure in the solid state was solved by X-ray diffraction 
analysis (see Table S2 for crystallographic details). X-ray quality crystals were obtained by 
slow diffusion of diethyl ether into a dichloromethane solution of complexes 2-PF6 and 10 and 
into an acetonitrile solution of complexes 3-PF6 and 6-PF6. ORTEP views of 2-PF6, 3-PF6 and 
6-PF6 with the atom labelling schemes are shown in Figure 3 and selected bond lengths and 
angles collected in Table S3. In the gold(III) complexes the gold atom displays a tetrahedrally 
distorted square-planar coordination. Bond parameters involving the cyclometalated C^N^N 
ligand can be compared with those found for the parent compound 1Cl-AuCl438 and for 
[Au(bipydmb-H)(SPh)[PF6].37 Small but significant differences are found for the Au-N2 bond 
lengths of the three complexes due to the different trans-influence of the donor atom of the 
trans-disposed ancillary ligand. The six-membered metallacycle Au1-N2-C10-C11-C12-C17 in 
2-PF6, 3-PF6 and 6-PF6 is in a boat conformation and the phenyl ring and the two pyridine rings 
are not coplanar; the methyl in axial position points to the metal centre with Au1 … H18A 
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distances of 2.647, 2.576 and 2.853 Å, respectively, that is less than the sum of Au (1.80 Å) 
and H (1.20 Å) van der Waals radii.  
 
 
Figure 3. Molecular structures of 2-PF6 (A), 3-PF6 (B) and 6-PF6 (C) with ellipsoids set at 30% 
probability level. Hydrogens were omitted for clarity. Also omitted in A is a second, partially occupied 
PF6−; symmetry operation to generate equivalent atoms: 1–x,1–y,1–z. In B a molecule of acetonitrile 
was omitted. 
 
 
Analysis of packing interactions shows that 2-PF6 forms a dimeric aggregate with a 
neighbouring unit via short O···H contacts between the carbonyl oxygen O(4) and hydrogen 
atom H(2) [O(4)···H(2)i 2.374 Å, i = 1–x,–y,–z] (Figure S17-18). The solid state structure 
develops further through π-stacking interactions between neighbouring phenyl rings of two 
cyclometalated ligands [mean plane distance C(12)-C(17)···C(12)ii-C(17)ii = 3.605(5) Å, ii = 1–
x,1–y,1–z] (Figure S19); the rings are slightly slipped [centroid-centroid distance 3.998(4) Å] 
and parallel to each other [plane twist angle 0.0(8)°], with their interaction aided by an 
additional hydrogen contact which locks the conformation [O(2)···H(14)ii 2.374 Å, ii = 1–x,1–
y,1–z] (Figure S18-19). Significant intermolecular long-range interactions are also present in 3-
PF6, which displays a ladder-type arrangement. Such a conformation comprises four molecular 
units interlocked via π-stacking of two coumarins sandwiched between two phenyl rings of the 
cyclometallated ligand [mean plane distance coumarin-phenyl 3.672(2) Å; mean plane 
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distance coumarin-coumarin 3.506(3) Å, see Figure S20]; the coumarins are stacked in a 
similar fashion to what observed for complex (C^Npz^C)AuS-4-methylcoumarin [C^Npz^C = 
N2C4H2 {Ph(
tBu)}-2,6].5 Finally, complex 6-PF6 shows intermolecular π-stacking interactions 
between the pyridyl and aminopyridyl rings of two adjacent units [centroid-centroid distance 
N(1)-C(5)···C(22)i-C(27)i 3.710(2), mean plane N(1)-C(5) to C(22)i 3.326(6) Å, i = 2–x,1–y,1–z; 
twist angle 5.83(17)°] (Figure S21). Additionally, the akynyl unit C(20)≡C(21) displays a short 
contact with a neighbouring alkynyl fragment [alkynyl···alkynyl 3.527(7) Å], thus contributing to 
the stacked conformation of the complex in the solid state (Figure S22). 
An ORTEP view of compound 10 with the atom labelling scheme is shown in Figure 4 and 
selected bond lengths and angles reported in the caption to the figure. Compound 10 displays 
a nearly linear geometry around the Au center [C1−Au1−P1 = 173.5(2)°], featuring an alkyne 
ligand [Au1−C1 = 1.999(5) Å; C1−C2 = 1.180(8) Å] and an ancillary triphenylphosphane ligand 
[Au1−P1 = 2.266(2) Å]. 
 
 
 
Figure 4. Molecular structure of compound 10 with ellipsoids set at 30% probability level. Hydrogens 
have been omitted for clarity. Selected bond lengths (Å) and angles (deg.): Au1-C11.999(5), Au1-P1 
2.266(2), C1-C2 1.180(8); P1-Au-C1 173.5(2), Au1-C1-C2 170.7(5), C1-C2-C3 177.4(6). 
 
 
Packing analysis shows no significant π-stacking interactions in the solid state structure, with 
the closest contact being between one the phenyl rings of the PPh3 [C(31)-C(36)] fragment 
and the bridging phenyl linker of the alkynyl ligand, C(3)-C(8), [3.911(3) Å; twist angle 
16.8(2)°]. 
 
Antiproliferative Properties 
The antiproliferative properties were assessed by monitoring the ability of the investigated gold 
complexes to inhibit cell growth using the classical MTT assay as described in the 
Experimental section. Initially, the compounds were tested against human lung epithelial 
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cancer (A549) and human ovarian cancer (SKOV-3) cancer cells. Table S4 in the 
supplementary material summarizes the preliminary obtained EC50 data of all complexes in 
these two cell lines. According to the obtained results, only complexes 3-PF6 and 5-PF6 
display antiproliferative effects, with 5-PF6 being the most efficient, while all the others are 
scarcely or non-active in both cell lines. Of note, all the free ancillary ligands showed EC50 
values above 50 µM (data not shown). Moreover, the AuI complex [Au(C2ArNHCOQ)(PPh3)] 
(10), featuring the same ancillary ligand as 5-PF6, showed very moderate effects in cancer 
cells (Table S4). 
Thus, the most effective compounds 3-PF6 and 5-PF6 were evaluated in other cell lines, 
including human breast cancer (MCF-7), human melanoma (A375), and the non-tumorigenic 
human embryonic kidney (HEK-293) cells. The resulting EC50 values are shown in Table 1 and 
compared to those of cisplatin and of the free ancillary ligand of complex 3-PF6, 
HC2ArNHCOQ. In general, compound 3-PF6 behaves similarly to cisplatin in the A549 and 
SKOV-3 cell lines. Instead, 5-PF6 is a far better inhibitor of cell proliferation than cisplatin, 
leading to the hypothesis that the compound may be active via different mechanisms. 
Unfortunately, while 3-PF6 is scarcely toxic against the non-tumorigenic HEK-293 cells, 5-PF6 
shows scarce selectivity.  
It should be noted that the observed differences in antiproliferative effects may be due 
to various reasons, including the stability of the compounds in aqueous solution, as well as 
possible differences in their intracellular accumulation profiles. Previously reported studies 
have shown that this type of AuIII C^N^N complexes - [Au(bipydmb-H)X]+ - possess high redox 
stability in aqueous solution while they tend to hydrolyse the ancillary X ligands to form 
[Au(bipydmb-H)(OH)]+.21,22 However, in order to further explore the differences among the 
biological properties of the compounds, we have studied the stability of the most active 
complexes 3-PF6 and 5-PF6 in comparison to the one of the least cytotoxic analogue 6-PF6 
(see Table S4) by UV-visible spectrophotometry. Figure S23 shows the representative 
absorption spectra of the two complexes 5-PF6 and 6-PF6 recorded in PBS (pH 7.4) at 
different times over 24 h. As it can be observed, complex 5-PF6 is perfectly stable during time 
(Figure S23A), and similar results have been obtained for complex 3-PF6. Conversely, 6-PF6 
undergoes marked spectral changes due to fast hydrolysis and possibly reduction of the 
gold(III) centre, as witnessed by the immediate disappearance of band centred at 320 nm, 
characteristic of the {AuIII(bipydmb-H)} scaffold (Figure S23B). The stability of 5-PF6 in the 
presence of the intracellular reducing agent glutathione (GSH) has also been studied by UV-
Vis spectrophotometry (Figure S24), and the results shows that the compound is able to form 
adducts with GSH right after mixing the two components. 
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Table 1. EC50 values determined after 72 h of exposure to the gold complexes 3-PF6 and 5-PF6 and the 
respective free ligands MeQS and HC2ArCONHQ.  
 
 Effective Concentration (EC50 / µM)a 
Compound A549 MCF-7 SKOV-3 A375 HEK-293 
3-PF6 17.6  2.4 - 15.1  1.9 44.15  12.30 54.38 ± 9.04 
5-PF6 4.5  0.8 2.3  0.8 2.6  0.8 1.46  1.07 0.55  0.01 
HC2ArNHCOQ >100 >100 >100 >100 >100 
MeQS >80 >80 >80 >80 >80 
cisplatin 11.5  0.9 20 3 13 4 3.10 1.59 8.15  0.47 
a Mean ± ES of three independent experiments performed with triplicate cultures at each tested 
concentration. 
 
 
Mass spectrometry 
Reaction with cytochrome c, cysteine and histidine 
Investigating the stability and ligand exchange reactions of putative metallodrugs is important 
for implementing their further design. ESI MS is ideally suited for this purpose because the m/z 
information allows conclusions on the mechanisms of reactivity of metallodrugs at a molecular 
level.42-43 Thus, compounds 1OH-PF6, 5-PF6, 6-PF6 and 9-PF6 were incubated with the model 
protein cytochrome c (cyt c) at 3:1 metal-to-protein ratio for 24 h at 37 °C, and with the amino 
acids cysteine and histidine at different incubation time (10 min, 1, 3 and 24 h) at 1:1 metal-to-
amino acid ratio. Of note, all the tested compounds did not form any adducts with the protein 
cyt c (data not shown). Intriguingly, the dinuclear oxo-bridged analogue39 of 1OH-PF6 reacted 
with cyt c, as studied by high-resolution LTQ-Orbitrap ESI MS, by forming mono- and bis-
adducts containing [AuIII(bipydmb-H)]2+ fragments.44 Moreover, all the new AuIII compounds do 
not react with histidine but they form adduct with cysteine (Figure 5), made exception of 6-PF6 
which results completely unreactive in the selected experimental conditions (data not shown). 
Formation of [Au(bipydmb-H)Cys]+ adduct begins after 1 h incubation and generally increases 
over time in all cases. This is in line with our previously reported ESI MS data on the reactivity 
of the hydroxo precursor [Au(bipydmb-H)(OH)][PF6] 1OH-PF6,45 forming predominantly 
monomeric AuIII adducts. A summary of the obtained data for the investigated compounds 
reacting with Cys after 24 h incubation is provided in Table 2 and Figure 5. The lack of 
reactivity of 6-PF6 with biomolecules, together with its pronounced instability, may also be 
responsible for its scarce cytotoxicity against cancer cells. 
 
Table 2. Experimental (mexp) and theoretical (mtheor) mass signals attributed to each specie during ESI-
QTOF MS experiments of compounds 1OH-PF6, 5-PF6 and 9-PF6 reacting with Cys after 24 h 
incubation. All experimental mass signals include a standard deviation of m/z of 0.05. 
 
Compound Species mexp mtheor 
1OH-PF6 [Au(bipydmb-H)OH]+ 487.16 487.11 
 [Au(bipydmb-H)Cys]+ 590.16 590.12 
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5-PF6 [Au(bipydmb-H)OH]+ 487.16 487.11 
 [Au(bipydmb-H)Cys]+ 590.16 590.12 
 [Au(bipydmb-H)(C2ArNHCOQ)]+ 758.22 758.17 
9-PF6 [Au(bipydmb-H)Cys]+ 590.18 590.12 
 [Au(bipydmb-H)GS]+ 776.26 776.18 
 
 
 
 
Figure 5. Representative ESI-MS spectra and peak assignments of complexes 1OH-PF6, 5-PF6 and 9-
PF6 with cysteine (1:1, 150 M) after 24 h incubation. 
 
 
 
Competitive Reaction with ubiquitin and model DNA 
Capillary zone electrophoresis (CZE)–ESI MS turned out to be ideally suited to investigate the 
binding preferences of metallo(-pro)drugs towards mixtures of protein and DNA und 
competitive conditions.35,46 CZE separates analytes according to charge and size and is thus 
ideally suited to separate hydrolysis products of metallo(-pro)drugs as well as potential 
adducts with biomolecules. Therefore, ubiquitin (ub), a widely used model peptide for 
interaction studies featuring a N-terminal methionine residue and a histidine,43 and a single 
strand oligonucleotide (5´-dATTGGCAC-3´) were mixed in aqueous solution with 1OH-PF6 in a 
1:1:4 molar ratio, incubated at 37 °C and reaction aliquots were analyzed after 10 min, 1 h and 
6 h (see Experimental for details). Under these conditions, and already after 10 min 
incubation, a large portion of the DNA has reacted with the gold compound producing 
[DNA + n{Au(bipydmb-H)}] (n = 1-4) adducts, while adducts with ub were not observed 
(Table 3). The unreacted cation of 1OH-PF6 was found at all three incubation time points with 
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the highest intensities at 10 min (Figure 6). All the analytes were baseline-separated in time by 
CZE. After 10 min the bis-adduct gave the highest product signal intensities, whereas after 6 h 
the tris-adduct showed the most intense peak. Thus, the DNA oligomer seems to feature three 
stable binding sites on the nucleotides, which are kinetically favored over amino acid binding. 
Overall, these results show the pronounced reactivity of the compound with oligonucleotides 
with respect to peptides and amino acids.  
 
 
Table 3. List of experimental (mex) and theoretical (mtheor) mass signals attributed to each species 
observed in CZE–ESI-MS experiments for 1OH-PF6. The accuracy of the mass signals is expressed as 
the deviation in parts per million (Δppm). 
 
Species mexp mtheor Δppm 
[1OH]+ 487.1111 487.1079 6.6 
[Au(bipydmb-H)(COOH)]+ 515.1051 515.1028 4.5 
[ub + 9H]9+ 952.6383 952.6329 5.7 
[DNA + 4{Au(bipydmb-H)} - 3H]5+ 857.3735 857.3698 4.3 
[DNA + 3{Au(bipydmb-H)} - 2H]4+ 954.4416 954.4379 3.9 
[DNA + 2{Au(bipydmb-H)}]4+ 837.4201 837.4153 5.7 
[DNA + Au(bipydmb-H) + H]3+ 960.1909 960.1880 3.0 
[DNA + 3H]3+ 803.8268 803.8237 3.9 
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Figure 6. (A) Representative extracted-ion-electropherograms (EIEs) of 1OH-PF6 incubated with 
ubiquitin (ub) and the oligonucleotide 5’- dATTGGCAC-3’ (DNA) for 10 mins and 6 h. (B) Experimental 
and simulated mass spectra of the most intense [1OH]-DNA adducts obtained by CZE–ESI-MS. 
 
 
 
Conclusions 
The synthesis of a new series of (C^N^N) cyclometalated AuIII complexes featuring the 6-(1,1-
dimethylbenzyl)-2,2’-bipyridine) scaffold has been reported and the compounds have been 
characterized via different methods, including some by X-ray diffraction. All the complexes 
were studied for their absorption and photophysical properties, showing typical IL and MLCT 
absorption bands in the UV-Vis region, while they feature a main emission band centred 
around 350 nm which is largely attributable to the bipydmb ligand. Unfortunately, the 
photoactive ancillary ligands quench their fluorescence upon binding to the AuIII centre, most 
likely due to an ISC relaxation path favoured by the gold metal ion. 
The compounds were evaluated for their antiproliferative properties in vitro and their 
activity was shown to be highly dependent on the nature of the ancillary ligand. Specifically, 
both AuIII complexes 3-PF6 and 5-PF6, featuring coumarin ligands, showed the most 
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pronounced anticancer activity, although 5-PF6 displayed scarce selectivity towards cancer 
cells with respect to non-tumorigenic ones. In the future, the selectivity of the compound may 
be improved tethering it to targeting peptides via derivatization of the cyclometalated scaffold. 
The stability of representative complexes (3-PF6, 5-PF6 and 6-PF6) in aqueous environment 
has been studied by UV-Vis spectrophotometry, showing that the least cytotoxic complex 6-
PF6 is also very unstable in solution. Moreover, the reactivity of selected AuIII C^N^N 
complexes was evaluated with model biomolecules by MS approaches and the results strongly 
point toward a preferred binding affinity for nucleic acid structures with respect to proteins, at 
variance with what has been observed so far for other types of cyclometalated AuIII 
compounds (e.g. of the C^N type). Due to the fact that only two AuIII derivatives out of eleven 
compounds tested showed appreciable antiproliferative activity, it is difficult to draw 
meaningful structure-activity relationships. However, it can be hypothesized that several 
factors can be responsible for the scarce anticancer effects displayed by the majority of the 
AuIII complexes: i) scarce reactivity with biomolecules, ii) reduced stability in aqueous 
environment, and iii) scarce cell uptake/accumulation. Thus, although these preliminary results 
may constitute the basis for the design of organogold compounds targeted to nucleic acid 
structures, further studies are necessary to gain mechanistic insights. Overall, while some of 
the compounds display promising anticancer activities and the selected scaffolds constitute 
attractive leads for further drug design, the quest for selectivity of such complexes toward 
cancer cells still needs to be addressed. 
 
 
Experimental section 
 
General. All reactions were carried out under air and solvents were dried and distilled before 
use. The precursors [Au(bipydmb-H)Cl][PF6] (1Cl-PF6), [Au(bipydmb-H)(OH)][PF6] (1OH-PF6), 
[Au(bipydmb-H)(OMe)][PF6] (1OMe-PF6), [Au(bipydmb-H)(CH2COCH3)][PF6] (1CH2Ac-PF6) were 
synthesized according to procedures reported in refs.36-38 The analytical data obtained for 
these four complexes were in agreement with published data. All other reagents and ligands, 
with the exception of HC2ArNHCOQ, were purchased from the Sigma-Aldrich. Infrared spectra 
were recorded with a Jasco FTIR 480 Plus spectrophotometer using Nujol mulls. UV−Vis 
spectra were recorded on a Varian Cary 50 or on a Hitachi U-2010 UV−Vis Thermo Nicolet 
Evolution 300 (190–1100 nm) spectrophotometer at room temperature using quartz cuvettes 
with an optical path length of 10.0 mm; spectra were recorded on MeCN solutions. Emission 
and excitation spectra were obtained at room temperature with a Varian Cary Eclipse 
Fluorescence spectrophotometer (Xe lamp) using quartz cuvettes with an optical path length 
of 10.0 mm. Absorption and emission electronic spectra were recorded on MeCN and CH2Cl2 
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solutions. 1H, 13C, and 31P NMR spectra were recorded at room temperature (20 °C) on a 
Bruker Avance III 400 spectrometer operating at 400.0, 100.5 and 161.8 MHz, respectively. 
Chemical shifts are given in ppm relatively to internal TMS (1H), and external H3PO4 (31P). 
 
Syntheses 
Synthesis of the ligand HC2ArNHCOQ.  
 
To a stirred solution of QCO2H (0.500 g, 2.6 mmol) in dichloromethane (5 mL) were added the 
coupling agent N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) (0.419 g, 2.7 mmol, d = 
0.877 g/mL) and a dichloromethane solution (2 mL) of HC2ArNH2 (0.340 g, 2.9 mmol) at room 
temperature. The reaction mixture was then cooled to 0°C and stirred for 24 h. The resulting 
yellow solid was filtered under vacuum and washed with water, ethanol and diethyl ether (58% 
yield). 1H NMR (CDCl3); assignments based on COSY and NOESY experiments: δ 3.05 (s, 
1H; HC2), 7.41 (t, part. overlapped, 1H, J = 7.2 Hz; H6), 7.44 (d, part. overlapped, 1H, J = 8.8 
Hz; H8), 7.49 (d, 2H, J = 8.0 Hz; Hm), 7.70 (t, part. overlapped, 1H, J = 8.0 Hz; H7), 7.71 (d, 2H, 
J = 8.8 Hz; Ho), 7.72 (d, part. overlapped, 1H, H5), 9.00 (s, 1H; H4), 10.92 (s, 1H; NH). 13C 
NMR (CDCl3): δ 77.4 (C≡CH), 83.6 (C≡CH), 117.0 (C8), 118.4, 118.6, 118.9 (C3, C9, Cp’), 
120.4 (Co), 125.8 (C6), 130.2 (C5), 133.2 (Cm), 134.8 (C7),138.3 (Cp), 149.4 (C4), 154.7 (C9), 
159.6 (C2), 162.0 (C1). Selected IR bands (νmax cm-1): 3270 ν(NH), 1702 ν(C=O). UV-vis 
[CH3CN, λmax/nm (ε/M-1cm-1)]: 261 (13002), 304 (14747), 336 (16206). 
 
Syntheses of the cyclometallated gold(III) complexes based on bipydmb  
 
 
[Au(bipydmb-H)(QCO2)][PF6] (2-PF6). To a stirred solution of 1OH-PF6 (0.0632 g, 0.1 mmol) in 
dichloromethane (5 mL) was added QCO2H (0.019 g, 0.1 mmol). The reaction mixture was 
stirred at room temperature for 3 h. A white solid which formed was filtered under vacuum and 
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recrystallized from dichloromethane/diethyl ether to give the analytical sample. Yield 83%; mp 
220 °C. Anal. Calcd for C29H22AuF6N2O4P: C, 43.30; H, 2.76; N, 3.48%. Found: C, 43.18; H, 
2.60; N, 3.39%. 1H NMR (CD3CN): δ 2.14 (s, 6H; CH3), 7.18 (td, 1H, J = 7.6, 1.6 Hz; H4’’), 7.37 
(td, 1H, J = 7.6, 1.2 Hz; H5’’), 7.42 (t, part. overlapped, 1H, J = 7.6 Hz; H6x), 7.43 (d, 1H, J = 
7.6 Hz; H8x), 7.51 (dd, 1H, J = 8.0, 1.6 Hz; H6’’), 7.66 (dd, 1H, J = 8.0, 1.2 Hz; H3’’), 7.73 (td, 
1H, J = 8.0, 1.6 Hz; H7x), 7.79 (dd, 1H, J = 8.0, 1.2 Hz; H5x), 8.02 (ddd, 1H, J = 7.6, 5.6, 1.2 Hz; 
H5’), 8.21 (dd, 1H, J = 6.4, 2.8 Hz; H5), 8.47-8.52 (m, 3H; H3 + H4 + H4’), 8.60 (d, 1H, J = 8.0 
Hz; H3’), 8.64 (s, 1H; H4x), 9.02 (dd, 1H, J = 5.6, 1.2 Hz; H6’). Selected IR bands (νmax cm-1): 
1728 ν(C=O), 1708 ν(CO2 asym), 1608, 1322 ν(CO2 sym), 842 ν(PF6). UV-vis [CH3CN, 
λmax/nm (ε/M-1cm-1)]: 299 (18471), 255 (sh, 12900), 305 (17300), 326 (17900). Emission 
spectrum, (λem nm) = 410. X-ray quality crystals of 2-PF6 were obtained by slow diffusion of 
diethyl ether into a concentrate dichloromethane solution. 
[Au(bipydmb-H)(MeQS)][PF6] (3-PF6). To a stirred solution of 1OH-PF6 (0.0632 g, 0.1 mmol) in 
dichloromethane (5 mL) was added solid MeQSH (0.019 g, 0.1 mmol). The resulting reaction 
mixture was stirred at room temperature for 24h. An orange solid which formed was filtered 
under vacuum and recrystallized from dichloromethane/diethyl ether to give the analytical 
sample. Yield 88%; mp 230 °C (dec). Anal. Calcd for C29H24AuF6N2O2PS: C, 43.19; H, 3.00; N, 
3.47%. Found: C, 43.05; H, 2.97; N, 3.41%.1H NMR (CD3CN); assignments based on COSY 
and NOESY experiments:δ 2.06 (s, 6H; CH3), 2.35 (d, 3H, J = 1.2 Hz; CH3), 6.20 (d, 1H, J = 
1.2 Hz; H3x), 7.08 (td, 1H, J = 7.6, 1.2 Hz; H4’’), 7.27 (ddd, 1H, J = 7.8, 7.4, 1.2 Hz; H5’’), 7.48 
(d, part. overlapped,1H, J = 8.4 Hz; H5x), 7.49 (dd, part. overlapped, 1H, J = 8.0, 1.6 Hz; H6’’), 
7.56 (dd, 1H, J = 8.4, 2.0 Hz; H6x), 7.60 (d, 1H, J = 2.0 Hz; H8x), 7.95 (ddd, 1H, J = 7.6, 5.6, 1.2 
Hz; H5’), 8.09 (dd, 1H, J = 7.6, 1.2 Hz; H3’’), 8.16 (dd, 1H, J = 8.0, 1.2 Hz; H5), 8.44 (t, part. 
overlapped, 1H, J = 8.0 Hz; H4), 8.46 (td, part. overlapped, 1H, J = 8.4, 1.6 Hz, H4’), 8.50 (dd, 
1H, J = 8.0, 0.8 Hz; H3), 8.58 (d, 1H, J = 8.0 Hz; H3’), 9.32 (dd, 1H, J = 5.6, 1.2 Hz; H6’). 
Selected IR bands (νmax cm-1): 1719 ν(C=O), 1596 ν(C=C) + ν(C=N), 842 ν(PF6). UV-vis 
[CH3CN, λmax/nm (ε/M-1cm-1)]: = 292 (17800), 306 (21000), 334 (21700). Emission spectrum, 
(λem nm) = 374. X-ray quality crystals of 3-PF6 were obtained by slow diffusion of diethyl ether 
into a concentrate acetonitrile solution. 
[Au(bipydmb-H)(CF3QNH)][PF6] (4-PF6). Method A: To a stirred solution of 1OH-PF6 (0.0632 g, 
0.1 mmol) in toluene (5 mL) was added solid CF3QNH2 (0.0229 g, 0.1 mmol). The reaction 
mixture was stirred at room temperature for 24h. A red solid which formed was filtered under 
vacuum and washed with Et2O. Recrystallization from dichloromethane/diethyl ether gave the 
analytical sample (29% yield). Method B: To a stirred solution of 1OMe-PF6 (0.0646 g, 0.1 
mmol) in dichloromethane (10 mL) was added solid CF3QNH2 (0.0687 g, 0.3 mmol). The 
reaction mixture was stirred at room temperature for 24h. A red solid which formed was filtered 
under vacuum and recrystallized from dichloromethane/diethyl ether to give the analytical 
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sample. Yield 50%; mp 230 °C (dec). Anal. Calcd for C29H22AuF9N3O2P: C, 41.30; H, 2.63; N, 
4.98%. Found: C, 41.35; H, 2.57; N, 5.03%. 1H NMR (CD2Cl2): δ 2.20 (s, 6H; CH3), 5.49 (s, 
1H, NH), 6.44 (s, 1H; H3x), 6.80 (s, 1H; H8x), 6.93 (d, 1H, J = 8.8 Hz; H6x), 7.11 (t, 1H, J = 7.6 
Hz; H4’’), 7.35 (t, 1H, J = 7.4 Hz; H5’’), 7.44 (d, 1H, J = 8.0 Hz; H6’’), 7.48 (d, 1H, J = 8.8 Hz; 
H5x), 7.55 (d, 1H, J = 8.0 Hz; H3’’), 7.99 (t, 1H, J = 6.8 Hz; H5’), 8.17 (d, 1H, J = 7.6 Hz; H5), 
8.52 (t, 1H, J = 7.4 Hz; H4), 8.54 (d, 1H, J = 7.6 Hz; H3), 8.55 (t, 1H, J = 8.0 Hz; H4’), 8.65 (d, 
1H, J = 8.4 Hz; H3’), 9.06 (d, 1H, J = 5.6 Hz; H6’). Selected IR bands (νmax cm-1): 1721 ν(C=O), 
1598 ν(C=C) + ν(C=N), 843 ν(PF6). UV-Vis [CH3CN, λmax/nm (ε/M-1cm-1)]: 248 (22600), 325 
(13300), 411 (11900). Emission spectrum, (λem nm) = 462. 
[Au(bipydmb-H)(C2ArNHCOQ)][PF6] (5-PF6). Method A. To a stirred solution of 1OH-PF6 
(0.0632 g, 0.1 mmol) in toluene (5 mL) was added solid HC2ArNHCOQ (0.0289 g, 0.1 mmol), 
1:1. The reaction mixture was refluxed at 80°C for 24h. A yellow solid which formed was 
filtered under vacuum, washed with Et2O and recrystallized from dichloromethane/diethyl ether 
to give the analytical sample (33% yield). Method B. To a stirred solution of 1OMe-PF6 (0.0646 
g, 0.1 mmol) in toluene (10 mL) was added solid HC2ArNHCOQ (0.0868 g, 0.3 mmol); a small 
amount of dichloromethane was then added until a solution was obtained. The reaction 
mixture was stirred at room temperature for 24h. The resulting solution was evaporated to 
dryness and the yellow residue recrystallized from dichloromethane/diethyl ether to give the 
analytical sample. Yield 61%. Method C. To a stirred solution of 1CH2Ac-PF6 (0.0672 g, 0.1 
mmol) in toluene (5 mL) was added solid HC2ArNHCOCoumar (0.0289 g, 0.1 mmol). The 
reaction mixture was refluxed at 80°C for 48h. A yellow solid which formed was filtered under 
vacuum and washed with Et2O; recrystallization from dichloromethane/diethyl ether gave the 
analytical sample. Yield 46%; mp 220 °C (dec). Anal. Calcd for C37H27AuF6N3O3P: C, 49.18; H, 
3.01; N, 4.65%. Found: C, 49.20; H, 2.97; N, 4.61%. 1H NMR (CD2Cl2): δ 2.16 (s, 6H; CH3), 
7.24 (t, 1H, J = 7.4 Hz; H4’’), 7.43 (t, 1H, J = 7.6 Hz; H5’’), 7.49 (d, 1H, J = 8.0 Hz; H6’’), 7.51 
(m, 2H; H6x + H8x), 7.58 (d, 1H, J = 8.0 Hz; H3’’), 7.67 (d, 2H, J = 8.0 Hz; Hm), 7.79 (t, 1H, J = 
8.0 Hz; H7x), 7.86 (d, broad, 3H, J = 7.2 Hz; H5x + Ho), 8.07 (t, 1H, J = 6.2 Hz; H5’), 8.19 (d, 1H, 
J = 7.2 Hz; H5), 8.29 (d, 1H, J = 8.0 Hz; H3), 8.54 (t, 1H, J = 8.0 Hz; H4’), 8.56 (t, 1H, J = 8.0 
Hz; H4), 8.68 (d, 1H, J = 8.0 Hz; H3’), 9.08 (s, 1H; H4x), 9.53 (d, 1H, J = 5.2 Hz; H6’), 11.03 (s, 
1H, NH). Selected IR bands (νmax cm-1): 3268 ν(NH), 1716 ν(C=O), 1609 ν(C=C) + ν(C=N), 
837 ν(PF6). UV-Vis [CH3CN, λmax/nm (ε/M-1cm-1)]: 262 (29100), 331 (32300). Emission 
spectrum (λem nm) = 365. 
[Au(bipydmb-H)(C2ArNH2)][PF6] (6-PF6). To a stirred solution of 1Cl-PF6 (0.0651 g, 0.1 mmol) 
in ethanol (5 mL) were added solid HC2ArNH2 (0.0117 g, 0.1 mmol) and an ethanol solution of 
tBuOK (0.0224 g, 0.2 mmol). The reaction mixture was stirred at room temperature for 24h. 
The resulting solution was evaporated to dryness and the orange solid recrystallized from 
dichloromethane/diethyl ether to give the analytical sample. Yield 45%; mp 210 (dec). Anal. 
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Calcd for C27H23AuF6N3P: C, 44.34; H, 3.17; N, 5.74%. Found: C, 44.30; H, 3.12; N, 5.69%. 1H 
NMR (CD3CN): δ 2.04 (s, 6H; CH3), 4.46 (s, 2H; NH2), 6.65 (dt, 2H, J = 8.4, 2.1 Hz; Ho), 7.17 
(td, 1H, J = 8.0, 1.6 Hz, H4’’), 7.36 (dt, part. overlapped., 2H, J = 8.4, 2.0 Hz; Hm), 7.37 (td, 1H, 
J = 6.8, 1.2 Hz; H5”), 7.57 (dd, 1H, J = 8.0, 1.6 Hz; H6’’), 8.03 (ddd, 1H, J = 7.6, 5.6, 1.2 Hz; 
H5’), 8.16 (dd, 1H, J = 7.2, 1.6 Hz; H3’’), 8.22 (dd, 1H, J = 8.0, 1.2 Hz; H5), 8.43 (t, 1H, J = 8.0 
Hz; H4), 8.44 (d, 1H, J = 7.2 Hz; H3), 8.47 (td, 1H, J = 8.0, 1.2 Hz; H4’), 8.56 (d, 1H, J = 8.0 Hz; 
H3’), 9.44 (dd, 1H, J = 5.4, 1.2 Hz; H6’). Selected IR bands (νmax cm-1): 3393 ν(NH), 2159 
ν(C≡C), 1623, 1605 ν(C=C) + ν(C=N), 841 ν(PF6). UV-Vis [CH3CN, λmax/nm (ε/M-1cm-1)]: 277 
(25922), 279 (27100), 316sh (16000), 400 (2200). Emission spectrum, (λem nm) = 351. 
[Au(bipydmb-H)(Sacc)][PF6] (7-PF6). To a stirred suspension of 1Cl-PF6 (0.0651 g, 0.1 mmol) 
in water (5 mL) was added an aqueous solution SaccNa (0.021 g, 0.1 mmol). The reaction 
mixture was left at room temperature for 24h. The resulting suspension was filtered under 
vacuum and washed with ethanol and diethyl ether and the white solid recrystallized from 
acetone/diethyl ether to give the analytical sample. Yield 71%; mp 255 °C. Anal. Calcd for 
C26H21AuF6N3O3PS: C, 39.16; H, 2.65; N, 5.27%. Found: C, 39.15; H, 2.67; N, 5.31%. 1H NMR 
(acetone-d6): δ 2.28 (s, 6H; CH3), 7.06 (t, 1H, J = 7.4 Hz; H4’’), 7.36 (t, 1H, J = 7.4 Hz; H5’’), 
7.50 (d, 1H, J = 8.0 Hz; H6’’), 7.58 (d, 1H, J = 7.2 Hz, H3’’), 8.01-8.11 (m, 4H; H2x + H3x + H4x + 
H5’), 8.16 (d, 1H, J = 7.2 Hz, H5x), 8.46 (d, 1H, J = 8.0 Hz; H5), 8.70 (t, 1H, J = 8.0 Hz; H4), 8.78 
(t, 1H, J = 8.0 Hz; H4’), 8.95 (d, 1H, J = 8.0 Hz; H3), 9.03 (d, 1H, J = 8.0 Hz; H3’), 9.09 (d, 1H, J 
= 5.2 Hz; H6’). IR in Nujol (νmax cm-1): 1697 ν(C=O), 1602 ν(C=C) + ν(C=N), 1176 ν(SO2), 845 
ν(PF6). UV-Vis [CH3CN, λmax/nm (ε/M-1cm-1)]: 253sh (14900), 329 (9800); Emission spectrum, 
(λem nm) = 462. 
[Au(bipydmb-H)(GluS)][PF6] (8-PF6). To a stirred solution of 1OH-PF6 (0.0632 g, 0.1 mmol) in 
dichloromethane (5 mL) was added a solution of GluSH (0.0364 g, 0.1 mmol) in the same 
solvent. The reaction mixture was stirred at room temperature for 24h. the resulting light yellow 
solution was concentrated to a small volume and diethyl ether added to give a light yellow 
solid which was filtered under vacuum to give the analytical sample as a 1:0.2 mixture of two 
diastereomers (1H NMR criterium). Yield 82%; mp 175 °C. Anal. Calcd for C33H36AuF6N2O9PS: 
C, 40.50; H, 3.71; N, 2.86%. Found: C, 40.39; H, 3.66; N, 2.78%. 1H NMR (CDCl3): major 
species δ 1.90 (s, 3H; CH3), 1.95 (s, 3H; CH3), 1.97 (s, 3H; CH3), 2.03 (s, 3H, CH3), 2.10 (s, 
6H; CH3), 3.57 (d, broad, unresolved X part of an ABX spin system, 1H, J = 9.2 Hz; H5x), 3.95 
(dd, A part of an ABX spin system, 1H, JAB = 12.4 Hz; JAX = 2.2 Hz; CHAHB), 4.05 (dd, B part of 
an ABX spin system, 1H, JAB = 12.4 Hz, JBX = 4.4 Hz; CHAHB), 4.89 (d, 1H, J = 9.6 Hz; H1x), 
5.04 – 5.12 (m, 3H, H2x + H3x + H4x), 7.12 (t, 1H+0.2H, J = 8.0 Hz; H4’’), 7.32 (t, 1H+0.2H, J = 
7.8 Hz; H5’’), 7.46 (d, 1H, J = 7.6 Hz; H6’’), 7.90 (t, 1H, J = 6.6 Hz; H5’), 8.0 (d, 1H, J = 8.0 Hz, 
H3’’ / H5), 8.08 (d, 1H, J = 8.0 Hz; H5 / H3’’), 8.43 (t, 2H, J = 7.6 Hz; H4’ + H4), 8.64 (d, 1H, J = 
8.0 Hz; H3), 8.70 (d, 1H, J = 8.0 Hz; H3’), 9.42 (d, 1H, J = 4.8 Hz; H6’); minor species δ 1.98 (s, 
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part. overlapped, CH3), 2.01 (s, 0.6H; CH3), 2.08 (s, 0.6H; CH3), 2.12 (s, 1.2H; CH3), 3.77 (ddd, 
0.2H, J = 10.2, 4.4, 2.4 Hz; H5x), 4.20 (dd, A part of an ABX spin system, 0.2H, JAB = 12.6 Hz, 
JAX = 2.0 Hz; CHAHB), 4.30 (dd, B part of an ABX spin system, 0.2H, JAB = 12.6 Hz, JBX = 4.4 
Hz; CHAHB), 4.63 (d, 0.2H, J = 10.0 Hz; H1x), 5.15 – 5.28 (m, 0.6H; H2x + H3x + H4x), 7.38 (d, 
0.2H, J = 7.6 Hz; H6”), 7.82 (d, 0.2H, J = 8.4 Hz; H3’’ / H5), 7.97 (t, 0.2H, J = 7.6 Hz; H5’), 8.12 
(d, 0.2H, J = 8.4 Hz; H5/H3”), 8.50 (t, 0.4H, J = 8.0Hz; H4’+H4), 8.68 (d, part. overlapped, 0.2H, 
J = 7.6 Hz; H3), 8.75 (d, 0.2H, J = 8.0 Hz; H3’), 9.27 (d, 0.2H, J = 4.8 Hz; H6’). Selected IR 
bands (νmax cm-1): 1752 ν(CO2 asym), 1600 ν(C=C) + ν(C=N), 1226 ν(CO2 sym), 842 ν(PF6). 
UV-Vis [CH3CN, λmax/nm (ε/M-1cm-1)]: 256sh (18500), 322 (8700), 397 (370). Emission 
spectrum, (λem nm) = 359.  
[Au(bipydmb-H)(GS)][PF6] (9-PF6). To a stirred solution of 1OH-PF6 (0.0632 g, 0.1 mmol) in 
water (5 mL) was added an aqueous solution of GSH (0.0307 g, 0.1 mmol). The reaction 
mixture was stirred at room temperature for 24h. A light yellow solid which formed was filtered 
under vacuum and recrystallized from methanol/diethyl ether to give the analytical sample as a 
1:0.1 mixture of two species, likely bond isomers. Yield 65%; mp 180 °C (dec). Anal. Calcd for 
C29H33AuF6N5O6PS: C, 37.79; H, 3.61; N, 7.60%. Found: C, 37.76; H, 3.65; N, 7.57%.1H NMR 
(D2O): major species δ 1.95 (s, 6H; CH3), 1.99 (m, broad, 2H; CH2-2x), 2.43 (dt, 2H, J = 7.6 
Hz; CH2-3x), 2.96 (dd, A part of an ABX spin system, 1H, JAB = 13.4 Hz, JAX = 9.4 Hz; CHAHB-
5x), 3.30 (dd, B part of an ABX spin system, 1H, JAB = 13.4 Hz, JBX = 4.6 Hz; CHAHB-5x), 3.69 
(t, 1H, J = 6.4 Hz, H1x), 3.77 (s, 2H; H6x), 4.44 (pseudo t, 1H, J = 6.8, 6.0 Hz; H4x), 7.03 (t, 1H, 
J = 7.4 Hz; H4’’), 7.16 (t, 1H, J = 7.4 Hz; H5’’), 7.42 (d, 1H, J = 7.6 Hz; H6’’), 8.00 (t, 1H, J = 5.6 
Hz; H5’), 8.04 (d, 1H, J = 8.0 Hz; H3’’), 8.09 (d, 1H, J = 8.0 Hz; H5), 8.38 (t, 1H, J = 7.8 Hz; H4), 
8.49 (m, 2H; H3 + H4’), 8.59 (d, 1H, J = 8.0 Hz; H3’) 9.30 (d, 1H, J = 4.8 Hz; H6’); minor species 
δ 1.84 (s, 0.6H, CH3), 2.37 (dt, 0.4H, J = 7.6 Hz; CH2-3x), 3.07 (dd, A part of an ABX spin 
system, 0.2H, JAB = 14.0 Hz, JAX = 4.4 Hz; CHAHB-5x), 3.35 (s, 0.2H), 4.20 (pseudo t, broad, J 
= 7.6Hz; H4x), 7.49 (t, 0.2H, J = 9.2 Hz), 7.60 (d, 0.2H, J = 8.4Hz), 7.83 (d, 0.2H, J = 8.4 Hz), 
8.17 (d, 0.2H, J = 7.2 Hz), 8.74 (d, 0.2H, J = 6.0 Hz; H6’). Selected IR bands (νmax cm-1): 3620 
ν(OH), 3403 and 3271 ν(NH), 1726 and 1652 ν(C=O), 1601 ν(C=C) + ν(C=N), 1531 ν(C=O), 
1236, 845 ν(PF6). UV-Vis [CH3CN, λmax/nm]: 256sh, 327. Emission spectrum, (λem nm) = 357. 
 
Synthesis of the gold(I) complex 
[Au(C2ArNHCOQ)(PPh3)] (10). To a stirred solution of [AuCl(PPh3)] (0.0495 g, 0.1 mmol) in 
ethanol (5 mL) were added solid HC2ArNHCOQ (0.0289 g, 0.1 mmol) and an ethanol solution 
of tBuOK (0.0224 g, 0.2 mmol). The reaction mixture was stirred at room temperature for 24h. 
The resulting solution was evaporated to dryness and the yellow solid was recrystallized from 
dichloromethane/diethyl ether to give the analytical sample Yield 40 %; mp. 200 °C (dec) Anal. 
Calcd for C36H25AuNO3P: C, 43.19; H, 3.00; N, 3.47%. Found: C, 43.05; H, 2.97; N, 3.41%. 1H 
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NMR (CD2Cl2): δ 7.46 (d, 2H, J = 8.0 Hz; Hm), 7.50 (d, 1H, J = 8.4 Hz; H6), 7.52– 7.65 (m, 16H; 
PPh3 + H8), 7.69 (d, 2H, J = 8.0 Hz; Ho), 7.76 (pseudo t, 1H, J = 8.4, 7.6 Hz; H7), 7.82 (d, 1H, J 
= 7.6 Hz; H5), 9.06 (s, 1H; H4), 10.86 (s, 1H; NH). Assignments based on Cosy and Noesy 
experiments. 31P{1H} NMR (CD2Cl2): δ 42.2. Selected IR bands (νmax cm-1): 1713 ν(C=O), 1100 
ν(PPh3). UV-Vis [CH3CN, λmax/nm (ε/M-1cm-1)]: 238 (sh, 3800), 298 (3980), 302 (4100), 345 
(2800). Emission spectrum, (λem nm) = 434. 
 
X-Ray crystallography 
Crystals of 2-PF6, 3-PF6, and 10 were examined using a Xcalibur Oxford Diffraction 
diffractometer equipped with CCD area detector and mirror-monochromated Mo Kα radiation 
(λ = 0.71073 Å). Crystals of 6-PF6 were examined using a Bruker Apex II diffractometer, 
equipped with a CCD area detector and graphite-monochromated Cu Kα radiation (λ = 
1.54178 Å). Intensities were integrated from data recorded on 1° (2-PF6, 3-PF6 and 10) or 1.5° 
(6-PF6) frames by ω or φ rotation. Cell parameters were refined from the observed positions of 
all strong reflections in each data set. Analytical (2-PF6, 3-PF6 and 10) or multi-scan (6-PF6) 
absorption correction with a beam profile correction was applied.47 The structures were solved 
by direct methods48 (6-PF6 and 10) or with SHELXT49 (2-PF6 and 3-PF6) and were refined by 
full-matrix least-squares on all unique F2 values,48-50 with anisotropic displacement parameters 
for all non-hydrogen atoms, and with constrained riding hydrogen geometries; Uiso(H) was set 
at 1.2 (1.5 for methyl groups) times Ueq of the parent atom. The largest features in final 
difference syntheses were close to heavy atoms and were of no chemical significance. 
CrysAlisPro was used for control and integration,47 and SHELX48 and OLEX251 were employed 
for structure solution and refinement. ORTEP-352 and POV-Ray53 were employed and for 
molecular graphics. Crystallographic data are reported in Table S2. CCDC 1855896-1855899 
contain supplementary crystal data for this article. 
 
Cell viability Assay 
The human lung epithelial cancer cells A549, the human ovarian cancer cells SKOV-3, the 
human breast cancer cells MCF-7 and the human melanoma cells A375 were obtained from 
ATCC. The human embryonic kidney cells HEK-293 were obtained from Dr. Maria Pia 
Rigobello (University of Padova). Cells were cultured in DMEM supplemented with 10% FBS 
and 1% penicillin/streptomycin at 37°C under a humidified atmosphere of 95% air and 5% 
CO2. For the evaluation of growth inhibition cells were seeded in 96-well plates at a 
concentration of 8000 cells per well and grown for 24 h in complete medium. Dilutions of the 
AuIII complexes were freshly prepared from a prepared stock solution (10-2 M in DMSO) in 
aqueous media (DMEM). Cisplatin was purchased at Sigma-Aldrich and its stock solutions 
prepared in aqueous solution (10-3 M). After 24 h incubation, 200 μL of the compounds’ 
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dilutions were added to each well to obtain a final concentration ranging from 0 to 50 M, and 
the cells were incubated for additional 72 h. Afterwards, medium was removed and 3- (4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Fluorochem) in 10× PBS 
(Phosphate Buffered Saline, Corning) was added to the cells, at a final concentration of 
0.3 mg/mL and incubated for 3-4 h. Then, the MTT solution was discarded and replaced with 
DMSO to allow the formed violet formazan crystals to dissolve. The optical density was 
quantified in quadruplicates at 550 nm using a multi-well plate reader. The percentage of 
surviving cells was calculated from the ratio of absorbance of treated to untreated cells. The 
EC50 value was calculated, using GraphPad Prism software, as the concentration causing 50% 
decrease in cell viability, using a nonlinear fitting of cell viability vs [treatment], and presented 
as mean ± SEM of at least three independent experiments. 
 
ESI mass spectrometry  
Horse heart cytochrome c (cyt c) was purchased from Sigma (code C7752). Metal complexes / 
cyt c adducts were prepared in water, with a protein concentration of 50 M and a gold to 
protein ratio of 3:1. Metal complexes / amino acids adducts were prepared in water with amino 
acid (His and Cys) concentration of 150 M and a gold to amino acid ratio of 1:1 and 1:1:1 for 
the mix. The reactions were incubated over 24 h and ESI MS spectra recorded at different 
times (10 min, 3 h, 6 h, 24 h) at room temperature. Samples were analyzed by ESI-QTOF MS 
on a Water Synapt G2-Si spectrometer by direct infusion at a flow rate of 5 µL min-1. The 
specific conditions used for these experiments were as follows: capillary voltage 2.5 kV, 
sampling cone voltage 40 V, source offset voltage 80 V, source temperature 120 °C, 
desolvation gas temperature 500 °C, cone gas flow 50 L h-1, desolvation gas flow nebulizer 
flow 6.5 bar.  
 
Capillary Zone Electrophoresis (CZE)–ESI mass spectrometry 
Ubiquitin and 3-nitrobenzyl alcohol were purchased from Sigma-Aldrich and the 
oligonucleotide 5´-dATTGGCAC-3´ from Microsynth. Ammonium bicarbonate and formic acid 
were obtained from Fluka, and methanol and 2-propanol from Fisher. NaOH solution (1 M) 
was a product of Agilent Technologies. Ultrapure water was received from a Millipore 
Advantage A10 system (18.2 MΩ, ≤5 ppb TOC, 185 UV). Stock solutions of ubiquitin and the 
single-stranded DNA-oligomer (200 µM each) were prepared in water. The gold complex 1OH-
PF6 (20 mM) was dissolved in DMSO and diluted with water to a concentration of 1 mM. The 
stock solutions were mixed to yield final concentrations of 50 µM for each ub/DNA and 200 µM 
for the gold complex, and the reaction mixture was incubated at 37 °C at constant shaking 
(400 rpm) in the dark. Aliquots were taken after 10 min, 1 h and 6 h and stored in the freezer 
at –20 °C until measurement. 
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Measurements were performed on a G7100 capillary electrophoresis system (Agilent 
Technologies, Waldbronn, Germany) equipped with a diode-array detector (190-400 nm) and 
hyphenated with a coaxial sheath-flow CZE–ESI-MS Sprayer Kit (Agilent Technologies) to a 
high resolution time-of-flight (TOF) mass spectrometer (maXis 4G UHR-TOF, Bruker, Bremen, 
Germany). The fused silica capillary (undeactivated, 75 µm, Agilent Technologies, USA) was 
cut to a total length of 70 cm, a UV/Vis window was prepared at 23 cm and cleaned with 
isopropanol before installation. The capillary cassette temperature was set to 25 °C. 
Capillaries were flushed successively with HCl (1 M, 5 min, 950 mbar), water (1 min), NaOH 
(1 M, 10 min), water (1 min) and background electrolyte (BGE, 25 mM NH4HCO3, pH 7.9, 
20 min). A sheath liquid (isopropanol, methanol, water, formic acid and 3-nitrobenzyl alcohol; 
25/25/50/0.2/0.5, v/v/v/v/v) was used to close the electric circuit and help the ionization. The 
sheath flow of 3 µL/min was provided by a syringe pump (KDS 1000, KD Scientific Inc., 
Holliston, USA). Before sample injection, the capillary was rinsed with BGE for 1 min. Samples 
were injected hydrodynamically for 5 s at 50 mbar. Typical instrument parameters can be 
found in Table 4. ESI-MS data were analyzed and processed using ESI Compass 1.3 
DataAnalysis 4.0 (Bruker Daltonics). The extracted ion electropherograms (EIE) in the figures 
were obtained by selecting the appropriate mass-to-charge ratio including an offset of 
±0.05 m/z. 
 
Table 4. Typical instrument parameters of the CZE–ESI-MS analysis. 
CE system Agilent G7100 
Capillary fused-silica capillary, i.d. 75 µm, length 70 cm 
Background electrolyte 25 mM NH4HCO3, pH 7.9 
Separation Voltage 25 kV 
Sample Injection Hydrodynamic 50 mbar, 5s 
  
ESI-MS system Bruker maXis qTOF 
capillary voltage 4.5 kV 
gas flow 0.4 bar 
dry gas 4 L min-1 
dry heater 180 °C 
quadrupole energy 4 eV 
collision energy 8.0 eV 
ion cooler transfer time 70 µs 
Spectra Rate 1 Hz 
 
Supporting Information 
The Supporting Information, including compounds’ NMR analysis, photophysical studies, 
antiproliferative activity data, stability studies by UV-visible spectroscopy, as well as 
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crystallographic data analysis, is available free of charge on the ACS Publications website at 
DOI: XXXX. 
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TOC Graphic 
A new series of novel (C^N^N) cyclometalated gold(III) complexes have been characterized for their 
structural and spectroscopic properties. The compounds anticancer activities have been studied in vitro 
and their reactivity with model biomolecules has been elucidated by mass spectrometry techniques, 
evidencing an unexpected preference for binding to nucleic acids with respect to proteins and amino 
acids. 
 
 
